Fractyl Laboratories has announced that the FDA has granted Breakthrough Device Designation for Revita DMR (duodenal mucosal resurfacing) in patients with insulin-treated type 2 diabetes (T2DM). Fractyl’s REVITA-T2Di study is now enrolling in this patient population.
“We are thrilled to work closely with the FDA to accelerate the introduction of a potentially significant therapy for patients with type 2 diabetes who continue to struggle with the burden and risks of their disease,” said Dr Harith Rajagopalan, co-founder and CEO of Fractyl. “Breakthrough Designation provides recognition from the FDA of the potential value that Revita DMR can bring to patients and an opportunity for accelerated access for patients who need better treatment options.”
Revita DMR is a first-in-class intervention targeting the role of the intestine in metabolic disease. It is an outpatient procedural therapy that uses heat to resurface the lining of the upper intestine, an organ which plays an integral role in metabolic regulation. Fractyl’s preliminary clinical findings suggest that treatment with Revita DMR may decrease insulin resistance, improve glucose control, lower weight and reduce liver fat.
The goal of the Breakthrough Device programme is to provide patients and health care providers with timely access to certain medical devices that deliver more effective treatment of life-threatening or irreversibly debilitating diseases or conditions by speeding up their development, assessment and review.
Fractyl also announced that the Centers for Medicare and Medicaid Services (CMS) has approved CMS coverage of routine costs for Medicare patients in the REVITA-T2Di trial. All eligible participants will receive study-related health assessments at no cost; this CMS decision allows for reimbursement coverage to clinical research centres for certain trial-related expenses.
"Type 2 diabetes is not simply a disease of blood sugar, but a multi-organ pathology that leads to progressive pancreatic beta-cell failure, fundamentally caused by insulin resistance. We know that treatment alternatives to current drug therapy are desperately needed to address the type 2 diabetes epidemic,” said Dr Juan Carlos Lopez-Talavera, Chief Medical Officer of Fractyl. “Providing a therapy that could improve glucose to target range while reducing the need for injectable insulin would be a quantum leap forward for patients. Fractyl is committed to advancing Revita DMR through the clinical and regulatory process to make a potentially meaningful difference in the lives of patients who are affected by this serious, chronic disease.”
Fractyl is now enrolling patients in the REVITA-T2Di trial, which is designed to form the basis for a premarket submission to the FDA in the insulin-treated T2D patient population. The trial is a prospective, randomised, double-blind, sham-controlled study enrolling 300 patients at up to 35 sites around the world.
DMR has received FDA Breakthrough Device Designation and a European Union CE mark. In the US, the device has not yet been authorized for marketing, but is the subject of an FDA-approved Investigational Device Exemption study. The Revita DMR System may be available for investigational use in other regions.